New Parkinson disease studies offer insights into topics such as LRRK2 G2019S transgene activity, preclinical drug development, neuroprotection in Parkinson disease, and more. Scoll through the slides for links to the studies.
References1. Almeida KJ, deMacedo LP, Lemos de Melo Lobo Jofili Lopes J, et al. Modified Pfeffer Questionnnaire for Functional Assessment in Parkinson Disease. J Geriatr Psychiatry Neurol. January 2017; Epub ahead of print.2. Koprich JB, Kalia LV, Brotchie JM. Animal models of a-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci. July 2017; Epub ahead of print.3. Park J, LeeJW, Cooper SC, et al. Parkinson disease-associated LRRK2 G2019S transgene disrupts marrow myelopoisesis and peripheral Th17 response. J Leukoc Biol. July 2017; Epub ahead of print.4. West AB. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp Neurol. July 2017; Epub ahead of print.